Key result
Novel B-CT score stratifies bleeding risk in cancer-associated VTE better than prior scores.
Answers are grounded in this paper and cite their sources.
New bleeding risk score for anticoagulated cancer-associated VTE; leaves open external validation before clinical adoption.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Roldán et al. (2023) conducted an editorial in Cancer-associated venous thromboembolism (Ca-VTE). B-CT bleeding risk score was evaluated on Significant bleeding events. The novel B-CT score, derived from >15,000 patients, stratifies bleeding risk in cancer-associated VTE, where prior VTE bleeding scores showed external validation C-statistics of 0.52-0.71.
Synapse has enriched 10 related papers. Consider them for comparative context: